Scientists have made big leaps in understanding and treating many complex diseases now. With new tools like gene therapy, RNA medication, complex biologics, we can even aim at diseases that seemed untouchable before. But we must keep in mind that early research places were not made for today’s fast-changing science, states Brian Taylor, the CEO of SmartLabs, a company based in Boston. Furthermore, the older model of large-scale manufacturing and worldwide distribution no longer fits science innovators. They want to tackle rare conditions and create new precision drugs.
“Our methods to discover, make, sell, and deliver drugs need to change to protect the industry and use science to stop a lot of human pain,” explains Taylor. Speaking with Taylor, we discussed the changes in science and what it could mean for the future of medicine. Understanding the challenges, we also explored his view on how we can reach our goals.
Many things have changed quickly recently, especially in drug discovery and development. What do we need to adjust to support this? We have scientific discoveries that could possibly cure cancer and other unmanageable diseases. We could also solve rare genetic conditions and create breakthrough solutions that could significantly reduce human suffering. However, it is crucial to understand that these diverse and innovative therapies need advanced technologies
, specific expertise, and flexible labs and production solutions. We need to alter our strategies and infrastructure for these potential discoveries. That’s where SmartLabs really shines. We offer adaptable labs that can be tuned to any requirement, meaning we could change a biology lab into a chemistry lab within four to six weeks. That’s part of the reason why companies work with us. We’re currently going through an era characterized by amazing scientific innovation but also limited funding and a keen focus on lessening risk. How will the industry overcome this problem?
This time of fast scientific progress yet unstable funding offers its challenges. We must find ways to lessen risk without diminishing innovation. This also means that we need to thoughtfully use funds and maintain open collaboration. SmartLabs works on all three aspects. Our labs and resources are designed to be quickly adaptable as research advances. This results in less capital investment and running costs, fewer commitments, and it gives the flexibility to change direction whenever needed. This cost-effective method speeds up and makes development efforts safer. Our team also provides expert guidance and everyday working support, allowing researchers to concentrate on their work. Plus, we offer the first professional lab and manufacturing platform on a fractional basis, which supports the workflow throughout therapeutic development. Inside a SmartLabs space, researchers can connect with other professionals and exchange ideas, safeguarding patents in the process. We have both small start-ups and established firms among our clients at SmartLabs.
How does your model cater to their different requirements? We cater to programs of various sizes, from early discovery to manufacturing. We might have advanced customers with set workflows who only need infrastructure solutions. Other customers are at the early stages of their development, and they might need help in numerous areas. We work with them to form workflows and adjust environments to complement their research needs. In simple words, we do the extra work so they can focus on science. What do you think we need now to future-proof the industry and help utilize the potential of science for the benefit of patients? SmartLabs was created to tackle this same challenge. Everything we do now is aimed to gear the industry for success now and in the future, especially for the patients. As we look forward, I see data collection and data analysis becoming more and more essential.
If we can join forces and share these insights, we can achieve even more. To me, the collaborative nature of SmartLabs offers a promise – researchers work together with partners and different firms, collecting data and discovering important insights that propel discovery. All of this can happen while still safeguarding IPs. This method could be important in encouraging partnerships and fast-tracking the field of drug development and delivery. Founded in 2015, SmartLabs stands on the belief that modern science needs a new, adaptable resource infrastructure. Its aim is to secure the future of the industry and quicken the pace of scientific breakthroughs for all. For more information,
Leave a Reply